
Release date: 2026-04-01 16:28:41 Article From: Lucius Laos Recommended: 5
While effectively inhibiting tumor growth, erlotinib may also cause a range of side effects. These adverse reactions vary from person to person. Most patients may experience mild to moderate skin reactions, gastrointestinal discomfort, and other symptoms; some patients may also develop more severe symptoms.
Burning, tingling, numbness, or pain in the hands, arms, feet, or legs; cough or hoarseness; severe diarrhea; difficulty breathing or shortness of breath; fever or chills; lower back or side pain; painful or difficult urination; severe rash; tingling sensation; stabbing chest pain; tightness in the chest.
Blood in or black, tarry stools; blurred vision; chest pain or discomfort; constipation; convulsions (seizures); eye irritation or redness; inability to speak; pain or discomfort in the arms, jaw, back, or neck; severe abdominal pain; slurred speech; sudden severe chest pain; sudden severe headache; sudden severe weakness in the arm or leg on one side of the body; sweating; changes in vision; vomiting blood or coffee-ground-like material.
Gastrointestinal system: Acid reflux or sour stomach, belching, bloating or a feeling of fullness, mild diarrhea, flatulence, heartburn, indigestion, stomach upset, nausea or abdominal pain, passing gas.
Skin, hair and mucosal system: Skin blemishes, dry skin, hair loss, itching skin, papules, mild rash, thinning hair, swelling or inflammation of the mouth.
Ocular system: Burning, dryness or itching of the eyes; dry eyes; excessive tearing; redness, pain or swelling of the eyes/eyelids/conjunctiva.
Musculoskeletal system: Bone pain, difficulty moving, joint pain, joint swelling.
Nervous system: Dizziness, tremors, difficulty falling asleep or insomnia, impaired concentration.
Psychiatric system: Fear, depression or emptiness, irritability, loss of interest or pleasure, nervousness.
General symptoms: Abnormal cold intolerance, fatigue, swelling, weight loss.
Loosening of the fingernails or toenails; redness or pain around the nails.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2112025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4462024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2182025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2342025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2102025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2392025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2082025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: